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Abstract 
 
This paper presents a major overview for the non medical prescriber when considering prescribing an 
antipsychotic to have the optimum outcome. 
 
Key messages 
 Antipsychotics continue to be the cornerstone of therapy for the treatment of schizophrenia.   
 Outcomes depend on adherence with therapy.  
 Patient choice in therapy is as important as clinician choice.   
 There is no one drug fits all. 
 Second generation/atypicals are as effective as first generation/typical antipsychotics but not 
superior and can cause side effects with long term problems  
 The involvement of the patient in the treatment plan is necessary including initial and ongoing 
physical health monitoring 
 The drug costs are less than 5% of the burden of costs in the care of schizophrenia 
 
Introduction 
The most common intervention for the treatment of schizophrenia is the prescribing of antipsychotics. 
There is much discussion about the most suitable antipsychotic to choose, a first generation (typical) 
antipsychotic or a second generation (atypical) antipsychotic. The evidence does not suggest there is 
much difference in efficacy between antipsychotics but there are substantial differences in side effect 
profile (NICE 2014). The antipsychotic that is the exception is clozapine when there is significant 
evidence of efficacy over other antipsychotics and in particular a reduction in the risk of suicide (Meltzer 
et al 2003). First generation antipsychotics (FGAs) traditionally cause more movement disorders known 
as extra pyramidal side effects (EPSEs) and second generation antipsychotics (SGAs) are more likely to 
cause endocrine side effects in particular weight gain and links to diabetes. However individual 
antipsychotics have their own individual side effect profiles and it is an important role of the prescriber 
to understand the pharmacology of the individual antipsychotics including the most appropriate 
formulation for individual patients.  
This article will firstly, discuss the dopamine hypothesis is as a background to prescribing antipsychotics. 
Then, secondly issues in the choice of antipsychotic are discussed. Thirdly, prescribing considerations for 
first and second generation antipsychotics with an emphasis on side effect profiles are outlined. In 
conclusion the need to individualise the prescribing decision so that the patient is involved in the 
prescribing decisions about medication for them are made. 
 
Dopamine hypothesis 
 
The dopamine hypothesis of schizophrenia suggests that at least the positive symptoms of schizophrenia 
are due to hyperactivity of dopamine in the mesolimbic pathway in the brain. Antipsychotics block 
dopamine resulting in reduction in the positive symptoms e.g. hallucinations, delusions, aggression. 
Side effects that commonly occur can be due to blocking dopamine pathways in other areas of the brain. 
In particular blocking dopamine in the nigostriatal pathway results in movement disorders known as 
extrapyramidal side effects (EPSEs). Potent D2 blockers e.g. haloperidol are most likely to cause these. 
Although the majority of clinical trials used haloperidol as a comparator it is not currently as widely 
prescribed as the SGAs.  Blocking dopamine in the tuberoinfundibular pathway can result in increased 
prolactin release potentially resulting in breast enlargement and lactation. Sulpiride and risperidone 
have a particular side effect of raised prolactin. Other side effects can be due to the lack of specificity for 
dopamine receptors with other alpha adrenoreceptor and histamine receptor activity causing postural 
hypotension and sedation and antimuscarinic activity causing dry mouth, blurred vision and 
constipation. 
 
Table 1 Considerations for choice of drug 
• Patient Choice 
• Diagnosis 
• Licensed use within product licence and BNF limits 
• Prescribing Guidance 
– NICE 
– Local –Trust or Area Prescribing Committee 
– Formulary 
• Cost 
• Advance Directives 
• Informed patient consent /Concordance with the chosen regimen 
• Previous response 
• Side effects 
• Co-morbid psychiatric or medical condition 
– Drug-drug interactions 
– Ability to swallow oral formulations 
• Concurrent drug therapy 
• Metabolic changes associated with age, gender, ethnicity 
– Lower doses in older people 
• Physical health 
– Cardiovascular status 
– Smoker 
– Diabetes 
– Ability to swallow tablets 
– Lifestyle 
– Weight 
• Allergies and Sensitivities 
• Metabolic changes associated with age, gender, ethnicity 
– E.g Lower doses in older people  
• Medicines prescribed ie consider drug-drug interactions 
 
Choice  
The best choice of antipsychotic is the one the patient is comfortable to take and is most likely to adhere 
to in the longer term. There is a plethora of evidence based guidance available to support prescribers 
from NICE guidance to local prescribing formularies. There has been a lot of emphasis on the cost of 
individual antipsychotics, however safety and adherence have a very important part to play as it is 
shown that antipsychotic drug costs are less than 5% of the total burden of cost of schizophrenia 
(Lieberman et al, 2005, Jones et  al 2006). The CATIE study from the USA showed them to be 2.1% and 
the CUTLASS study from the UK to be 3.8%   of the overall cost of treatment.  
 
Medicine based evidence 
 
Much of the evidence has been developed by comparing haloperidol to the second generation 
antipsychotics risperidone, olanzapine, quetiapine and aripiprazole as they were developed for market 
(Healy, 2016).Two important studies that have informed choice and outcome from prescribing are the 
CATIE (USA) and CUTLASS (UK). In the CATIE study in the United States the comparator first generation 
antipsychotic was perphenazine, which, although available in the UK is not widely prescribed (Lieberman 
et al). A cohort study of primary care patients carried out between 2007 and 2011 (ref) showed the 
second generation antipsychotics to be more commonly prescribed for schizophrenia with the most 
common in primary care being risperidone, quetiapine and olanzapine.   Aripiprazole has only more 
recently become available as a generic and asenapine and lurasidone being more recently introduced 
there is less data available from primary care.  The prescribing of the FGAs, chlorpromazine, haloperidol 
and trifluoperazine reduced over the period of the study. In addition clozapine is normally prescribed in 
secondary care. Although NICE guidance recommends that both first and second generation 
antipsychotics should be considered first line it is clear that the majority of prescribing for schizophrenia 
falls to second generation antipsychotics with the use of typical antipsychotics for schizophrenia falling. 
In trials olanzapine caused most weight gain and dyslipidaemia, quetiapine caused most anticholinergic 
effects and risperidone caused the most hyperprolactinaemia and sexual side-effects compare to other 
SGAs. Perphenazine had highest rates of discontinuation for extrapyramidal side-effects, even though 
direct measures of these effects did not differ significantly between drugs.  
 
Choice and other variables in prescribing 
 
It is common to focus on the evidence base when prescribing however this requires to be backed up by 
the pharmacology of the drug, the physiological condition of the patient and the licensed indications for 
the individual antipsychotic. Evidence suggests that it is the length of treatment and adherence with the 
prescribed regimen that most improves patient outcome. It is also necessary to consider the licensed 
indications for the product particularly for use in adolescents and older people.  This information is 
readily available from the most up to date British National Formulary (BNF) and the summary of product 
characteristics (SPC), available from the electronic Medicines Compendium (eMC) at 
ww.medicines.org.uk, of the individual drugs (BNF 2016). 
 
The recent article on prescribing for schizophrenia in pregnancy (Hardy 2017) gave a full account of the 
individual drugs so it is not necessary to repeat this information here. A particularly useful reference 
source to support both clinician and patient choice is the “Choice and medication website” where there 
is information to support choice of one antipsychotic over another for both the prescriber and the 
patient. This is can be accessed via the http://www.choiceandmedication.org/swyp/.* 
Prior to initial prescribing and ongoing throughout the treatment period physical health monitoring is 
essential and pre-screening is helpful wherever possible (NICE, 2014). In particular for haloperidol an 
ECG is recommended prior to treatment. It may not always be possible to get this completed prior to 
starting treatment however it is important to continue to consider getting this test with reference to the 
mental state of the patient. 
 
It is important to consider the formulation of the antipsychotic when prescribing and to understand the 
pharmacokinetics of the antipsychotic and formulation being prescribed. Oral formulations are the most 
common with depot antipsychotics only being chosen normally there are adherence issues and if it 
convenient for the patient (Edward & Alderman, 2013).  
 
 
 
Prescribing considerations: First generation antipsychotics  
 
Chlorpromazine was the first antipsychotic to be widely prescribed but is no longer a treatment of 
choice for schizophrenia. It is used in doses of 75mg to 300mg daily with dose titration being important. 
It is a low potency antipsychotic, as well as blocking dopamine it affects muscarinic, histaminic and alpha 
-adrenoceptors and may cause sedation, hypotension and constipation. There is a risk of neutropenia, 
prolongation of the QT interval, increased susceptibility to sunburn, impairment of body temperature, 
retinal pigmentation all leading to reduction in prescribing. 
Haloperidol is a potent dopamine D2 blocker causing a high incidence of EPSEs. It is prescribed in doses 
of 2mg to 10mg per day ideally using dose titration with the lowest possible dose.  
Trifluoperazine is a potent D2 blocker used in doses of 5mg twice daily (increased if required). It causes 
EPSEs in particular dystonic reactions. 
Extra pyramidal side effects may be caused by blocking dopamine in the nigrostriatal pathway the brain. 
These can affect the patient in different ways in particular dystonia causing severe muscle stiffness and 
oculogyric crisis. This can be extremely distressing and it is important to understand that patients 
suffering from this are unlikely to be adherent to treatment regimens in the future. In the past these 
were usually identified by clinicians however there is now a generation of clinicians working in mental 
health who have not seen these side effects since the reduction in prescribing. These are well described 
in the BNF and include 
Akathisia  a feeling of inner restlessness which is very difficult to treat other than by changing the 
antipsychotic or redcing the dose 
Dystonia -Muscle spasms and oculargyric crisis which may be inceased in young males. This can be 
treated by using an antimucarinic e.g. procyclidie 
Drug induced Parkinsonism - tremor, slowing up which may be higher in elderly females. This can be 
treated by using an antimucarinic e.g. procyclidine 
Tardive Dyskinesia -lip smacking, tongue protrusion, pill rolling coming on in often after many years and 
it can be permanent. Gradual reduction of treatment and antimuscarinics is important. 
Neuroleptic Malignant Syndrome less than 1% -fever, rigidity, tachycardia, unstable BP, fluctuating 
consciousness. There can be very high creatinine phosphokinase (CPK) levels and altered liver function 
tests ( LFTs). Treatment requires stopping all antipsychotics. 
 
Anticholinergics (antimuscarinics) can be used to moderate the effects of EPSEs in particular dystonia 
and Parkinson’s type side effects. These are not likely to be effective for akathisia and may worsen 
tardive dyskinesia. Other strategies include lowering the dose or switching to an SGA 
Examples include 
– Trihexylphenidyl (Benzhexol) 
– Orphenadrine 
– Procyclidine 
• Can antagonise effects of antipsychotics 
• Side effects include  
– Dry mouth, blurred vision, constipation 
 
Prescribing considerations: Second generation antipsychotics (SGAs) 
 
Amisulpride is prescribed for schizophrenia with predominantly positive symptoms at doses 
between  400 and 800mg daily. It is normally administered twice daily. It has a low incidence of 
cardiotoxicity, sedation, EPSE’s & weight gain but a high incidence of prolactin elevation. It is 
available in generic form. 
 
Aripiprazole is prescribed as a once daily dose of 10mg to 20mg per day with a 5mg starting dose for 
older people. The licensed dose is up to 30mg per day but this is not routinely recommended due to 
lack of evidence of benefit. It has a low incidence of, weight gain, EPSE’s, cardiotoxicity & 
hyperprolactinaemia. Aripiprazole is the only atypical antipsychotic with partial agonistic activity at 
dopamine receptors. When dopamine levels are diminished, the partial agonistic activity of 
aripiprazole increases dopamine transmission due to a lower degree of occupation of dopaminergic 
receptors by dopamine.  
 
Risperidone is well tolerated at less than 6mg/day in adults, 4mg/day in older people. It has a low 
incidence of cardiotoxicity & EPSE’s. It may cause mild hypotension, mild weight gain & raised 
prolactin. It is available in an oro-dispersible preparation and a generic form.  It is also available as a 
depot preparation which can be administered at fortnightly dose intervals. 
 
Olanzapine  is prescribed at a dose of 10 to 20mg for schizophrenia. Starting doses are lower in 
older people. It has a low incidence of cardiotoxicity, EPSE’s & prolactin elevation. It may cause 
hyperglycaemia, moderate sedation & weight gain. It is available as an oro-dispersible preparation 
and in a generic form. It is also available as a depot preparation although there are strict post dose 
administration monitoring requirements which have reduced the usefulness of this preparation. 
 
Quetiapine is prescribed at doses of between 150mg to 750mg daily with twice daily dosing for the 
standard preparation and once daily dosing for the extended release preparation.  Dose titration is 
important and should be carried out as per the SPC. There are generic forms available but no depot. 
It has a low incidence of EPSE’s, cardiotoxicity & hyperprolactinaemia.   
 
Clozapine is the only antipsychotic drug recommended for treatment resistant schizophrenia and is 
licensed for use after an adequate trial of two antipsychotics of which one should be an SGA. There 
is evidence that clozapine can potentially reduce the risk of suicide. Its complex licensing 
arrangements make it more difficult to prescribe than other antipsychotics and as a result there is 
no depot preparation available. Dose titration is important with risks of hypotension and 
tachycardia if the doses are increased rapidly. Common dose regimens are between 300mg and 
600mg daily. There is a risk of neutropenia and full blood counts (FBC) are required weekly for 18 
weeks of treatment, 2 weekly until one year, monthly thereafter while treatment continues. Side 
effects include sedation hypersalivation seizures weight gain cardiomyopathy and constipation. It is 
contraindicated for use with depots antipsychotics, carbamazepine and any medicines that may 
lower white cell count. Potential drug interactions can be identified due to the effect on cytochrome 
P450 of enzyme inducers. A particular problem that always needs considering is the effect of 
tobacco smoke on clozapine levels. Stopping smoking can result in the raising of the clozapine level 
leading to increased side effects.  
 
Weight gain is a particular problem with SGAs. Clozapine and olanzapine are the highest risk, 
quetiapine and risperidone are moderate risk with aripiprazole and amisulpride the lowest risk. A 
study by Bobes et al 2003 showed that olanzapine and risperidone were risk factors for weight gain 
over haloperidol. 
Physical health monitoring is required throughout the course of treatment and this together with 
involving the patient in the treatment is the key intervention recommended in the NICE clinical 
guideline for psychosis and schizophrenia. (NICE 2016) 
 
 
 
Depot antipsychotics Do we need to include FGA depots and SGA depots in each section?? 
Depot antipsychotics were developed to support adherence with treatment. Full information on dosing, 
prescribing and administration of depot antipsychotics can be found in the document long acting 
intramuscular injections 5th edition https://hydra.hull.ac.uk/resources/hull:13659 (Feetam et al 2016). 
Prescribers should be aware of the pharmacokinetics of the depot antipsychotic being prescribed. There 
is no advantage to weekly injections although these are commonly prescribed in clinical practice. 
Information on the pharmacokinetics of depot antipsychotics can be found in the Psychotropic drug 
directory (Bazire 2016). The availability of both first generation and second generation depot has been 
shown to be important no long acting injection being clinically superior to another in a trial comparing 
the effectiveness of  flupenthixol, risperidone, and zulclopenthixol in clinical practice (Shajahn et al 
2010). There is emerging evidence that clozapine and depot antipsychotics have the highest rates of 
prevention of relapse in schizophrenia and reduced rates of re-hospitalization over other oral 
antipsychotics. This was evidenced in a nationwide study in Sweden of 29,823 patients run between 
2006 and 2013 (Tihonen et al 2016).  
 
 
 
 
 
Table 1  
First Generation Antipsychotics 
oral 
 
Chlorpromazine 75mg -
300mg daily  
in divided 
doses 
No longer 
commonly 
prescribed 
Haloperidol 2 -10mg  Potent D2 blocker 
may cause EPSEs 
Sulpiride  Risk of 
hyperprolactinaemia 
Trifluoperazine   
   
   
First generation depots  
Flupentixol 
decanoate 
50mg every 
4weeks to 
300mg 
every 2 
weeks 
Test dose of 20mg 
recommended 
Fluphenazine 
decanoate 
12.5mg 
(6.25mg 
Test dose of 12.5mg 
(6.25mg in elderly) 
elderly) – 
100mg 
every 2-
5weeks 
recommended  
Haloperidol 
decanoate 
50 mg -
300mg 
every 4 
weeks  
Test dose of 25mg 
recommended 
Zuclopentixol 
decanoate 
200mg -
5oomg 
every 1-
4weeks 
Test dose of 100mg 
recommended 
   
   
   
 
Second Generation antipsychotics oral Common side effects 
Amisulpride   
Aripiprazole   
Clozapine   
Olanzapine  Weight gain, dyslipidaemia 
Quetiapine  Antimuscarinic effects 
Risperidone   
Second generation  depots  
Aripiprazole 400mg monthly Treat with oral aripiprazole prior to injection 
Olanzapine 
pamoate  
monohydrate 
150mg-300mg every 4 
weeks 
Treat with oral olanzapine prior to injection 
Paliperidone 
palmitate 
75mg -150mg monthly 
after dose titration 
150mg day 1, 100mg day 8 then 75-150mg a month later 
Risperidone 25mg to 50mg every two 
weeks 
Treat with oral risperidone prior to injection. Continue for   
   
   
 
Conclusion 
 
This article has provided a practical background to prescribing antipsychotics. Antipsychotics can help 
the patients to live a meaningful and settled life when they experience the symptoms of psychosis 
and/or schizophrenia. However as shown in article the balance between the benefits and risks of 
prescribing antipsychotics need to be considered by the prescriber so that the optimisation of medicine 
is the outcome. Therefore the minimisation of side effects with the lowest dose of antipsychotic to treat 
symptoms needs to be at the foremost of the prescriber’s decision making. Finally involving patients in 
the prescribing decisions that are made about them is paramount. The best way to involve and get the 
best possible outcome is that patients are informed and agree with the prescription as appropriate to 
their lifestyle and health needs. This may be difficult when there are capacity issues but should still be at 
the forefront of all communication with the person who is prescribed antipsychotics. 
 
 
 
 
 
 
 
 
 
 
 
Further information is available in the handy chart for psychosis from the choice and medication website 
Always use the most up to date BNF and SPC when prescribing. 
 
 
*Choice and medication website is available by subscription via a link to the local mental health services 
website. The whole of Great Britain subscribe except Sheffield, South London and Maudsley (SLAM), 
Oxleas, Mersey Care and Lancashire Care who will have their own information sources. 
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